Independent
Tenure on this board
15.4 yrs
4 nominees · 3 ballot items.
Election of four Class A directors; approval to allow the Company to sell shares below net asset value in future offerings (subject to 1940 Act conditions and a 25% aggregate limit for 12 months); and approval to authorize the Company to issue warrants, options or rights to subscribe for, convert to, or purchase shares of common stock (subject to Section 61(a)(4) limitations).
Elect Michael J. Hagan, Jeffrey K. Harrow, James H. Kropp and Elizabeth J. Sandler as Class A directors for three-year terms expiring in 2029.
Approve authorization for the Company to sell its common shares below net asset value in future offerings to provide flexibility for raising capital; limited to aggregate sales of 25% of outstanding shares and effective for 12 months following stockholder approval.
This management proposal seeks stockholder approval under Section 63(2) of the Investment Company Act of 1940 to allow the Company to issue common shares at prices below then-current net asset value (NAV) for up to 12 months following approval, subject to board determinations and a cumulative cap of 25% of outstanding shares. Management frames this authority as a necessary tool to maintain rapid access to capital markets during periods of market stress or dislocation, enabling the Company to repay debt, seize opportunistic investments, and preserve regulatory asset coverage ratios. The Board’s recommendation emphasizes that a required majority of independent and non-interested directors must determine any such sale is in the Company’s best interests and must, in consultation with underwriters when applicable, determine in good faith that the sale price closely approximates market value less customary distribution fees. The proposal explicitly acknowledges dilution risks to existing stockholders, provides examples illustrating potential NAV dilution under hypothetical offerings, and describes safeguards including board oversight and the statutory conditions of the 1940 Act. The Board also considered conflicts of interest stemming from increased management fees driven by higher assets and concluded it would weigh benefits versus detriments before any issuance. While the Company has no immediate plans to sell below NAV, approving this proposal preserves optionality to act quickly when opportunistic or defensive capital needs arise, which could enhance long-term NAV if deployed into accretive investments. An important practical limit is that the authorization, if granted, covers offerings only for 12 months and caps aggregate issuances at 25% of outstanding shares; nonetheless, there is no limit on the discount that could be used, so board diligence and market consultation will be critical to limit shareholder harm. For investors evaluating the proposal, the core tradeoff is between immediate dilution risk and the strategic ability to shore up balance sheet and deploy capital into potentially value-enhancing opportunities during dislocations; board independence and process for pricing will be central to mitigating agency concerns.
Authorize the Company, subject to Section 61(a)(4) of the 1940 Act and board approval, to issue warrants, options or rights (which may include convertible preferred stock or debentures) to subscribe for, convert to, or purchase common shares; exercise/conversion features limited to 10 years and aggregate voting securities issuable on conversion not to exceed 25% of outstanding voting securities.
This management proposal requests stockholder approval to permit the Company to issue warrants, options or rights to subscribe for, convert to, or purchase common shares (potentially accompanied by convertible preferred stock or convertible debentures) as a financing and capital-raising tool. The authority would operate under Section 61(a)(4) of the 1940 Act and includes statutory conditions—exercise/conversion features must expire within 10 years, exercise/conversion price must be no less than current market value at issuance, and any issuance must be approved by a majority of non-interested and non-financially-interested directors as being in the Company’s and its stockholders’ best interests—while also limiting the aggregate voting securities issuable upon conversion to 25% of outstanding voting securities. Management argues this tool offers flexibility to raise capital in volatile or disrupted markets where direct equity or debt financing may be costly or unavailable, and is a common market practice that would put the Company in similar footing to other BDCs and corporations. The proposal signals no immediate issuance plans, emphasizing the Board’s role in setting specific terms and pricing at the time of any issuance and the need to consider dilutive effects and use of proceeds on a case-by-case basis. From a governance perspective, the statutory safeguards and board-level voting thresholds mitigate but do not eliminate dilution and agency concerns, particularly because the authorization has no expiration and could be used opportunistically; therefore investor protections depend on director independence and the rigor of pricing determinations. Economically, the instrument can be efficient for private placements or as deal sweeteners in structured financings, potentially allowing the Company to secure capital on better terms or participate in transactions that would otherwise be unavailable. Analysts should weigh the benefits of increased financing flexibility and potential accretive deployments against the dilution risk and the open-ended temporal authority, and monitor any future issuances for pricing, board approval process, and whether proceeds are deployed into value-enhancing investments.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | OAK HILL ADVISORS LP | 3.2% | 8,975,827 | $91M |
| 2 | VAN ECK ASSOCIATES CORP | 1.7% | 4,745,859 | $48M |
| 3 | UBS Group AG | 1.7% | 4,735,501 | $48M |
| 4 | LPL Financial LLC | 1.6% | 4,406,386 | $45M |
| 5 | Saba Capital Management, L.P. | 1.3% | 3,509,748 | $36M |
| 6 | Beach Point Capital Management LP | 1.1% | 3,129,787 | $32M |
| 7 | COMMONWEALTH EQUITY SERVICES, LLC | 0.9% | 2,553,908 | $26M |
| 8 | Generali Asset Management SPA SGR | 0.9% | 2,546,371 | $26M |
| 9 | Legal General Group Plc | 0.9% | 2,515,860 | $26M |
| 10 | CURA WEALTH ADVISORS, LLC | 0.8% | 2,264,934 | $23M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.